

Systemic Sclerosis

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) (FocuSSced)

Trial Status
Completed

Trial Runs In
22 Countries

Trial Identifier
NCT02453256 2015-000424-28
WA29767

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will assess the efficacy and safety of tocilizumab compared with placebo in participants with SSc across approximately 120 planned global study sites. The study will consist of a 48-week, double-blind, placebo-controlled period followed by a 48-week open-label treatment period. Participants will be assigned, in a 1:1 ratio, to double-blind treatment with active tocilizumab or matching placebo. In the open-label period, eligible participants from either arm may receive active tocilizumab.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02453256 2015-000424-28 WA29767
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No
